Designed to Secrete a Wide Range of Cancer Testis Antigens
Using our gp96 platform, the company has developed HS-110 as a treatment for patients with non-small cell lung cancer.
HS-110 is an off-the-shelf cell-based therapy. Our scientists have genetically engineered HS-110 to secrete a wide range of cancer testis antigens chaperoned by gp96 proteins.
In clinical trials, HS-110 demonstrated a broad activation of T-cell mediated immune response in cancer patients.